" class="no-js "lang="en-US"> FUJIFILM Cellular Dynamics and PhenoVista Biosciences Announce Strategic Alliance to Improve the Drug Discovery Process - Medtech Alert
Monday, February 26, 2024

FUJIFILM Cellular Dynamics and PhenoVista Biosciences Announce Strategic Alliance to Improve the Drug Discovery Process

FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cell (iPSC) technologies, and PhenoVista Biosciences (PhenoVista), a top provider of custom imaging-based phenotypic assay services, today announce a strategic alliance to improve the drug discovery process, by using iPSCs in screening. This alliance will enable drug discovery researchers and scientists access to services for phenotypic and High Content Screening (HCS) imaging using iPSC-derived differentiated cells, which are more biologically-relevant systems, to help in the drug discovery process.

The drug discovery industry continues to leverage human-derived iPSCs for the development of assays and models to provide increased biological relevance, which can help improve the overall efficiency and success of the discovery process. iPSCs are used to create disease models, enabling researchers to understand the human biology for a range of diseases, and screen for the best possible pharmaceutical drug candidates. Additionally, HCS using iPSCs is applied to create cell-based assays monitoring functions like mitochondrial health and synapse formation, while examining effects of drug candidates and/or environmental contaminants on individual cells.

As the preferred iPSC supplier for PhenoVista, FUJIFILM Cellular Dynamics will provide its portfolio of differentiated human cells and disease-relevant models in industrial quantities to support PhenoVista in the development of new assays for sophisticated HCS assay development for its customers. This alliance enables PhenoVista to conduct high-value screening programs using FUJIFILM Cellular Dynamics’ iPSCs to create multi-cell systems that enable analysis of 3D models. These models best recapitulate the biology of human tissues in an accessible format amenable to compound screening, thus enabling researchers to accelerate their drug development.

“Assays using human-derived iPSCs offer unparalleled capability when it comes to biological relevance and become even more valuable when combined with the advanced data analysis and insights inherent with high content screening,” said Dr. Keith R. Olson, senior vice president of commercial operations, FUJIFILM Cellular Dynamics, Inc. “With the capabilities and expertise resident in our two organizations, we are providing scientists and researchers with the ability to engage in these types of assays with lower risk and higher success in the drug discovery process.”

“Since founding PhenoVista in 2014, FUJIFILM Cellular Dynamics, Inc. has been our go-to source for iPSC-derived cells,” said Dr. James G. Evans, chief executive officer, PhenoVista Biosciences. “As a service provider, it’s critical that we have the best possible models to use on our client’s behalf. Leveraging the strength of PhenoVista’s scientists along with FUJIFILM Cellular Dynamics’ high quality cell models positions both organizations for accelerated growth in this fast-paced market.”

To access these services please visit https://phenovista.com/.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more